Breast Cancer

  • Dennis W. Ross


Breast cancer is our fourth and final clinical example of the principles of molecular oncology. In the previous chapters on leukemia/lymphoma, colon cancer, and squamous cell carcinoma of the cervix, we saw several common threads. Tumors develop as the result of a germline or somatic mutation in a tumor suppressor gene or oncogene. Invasive cancer is the endpoint of a multiple-step evolution that can be tracked as a series of progressive histologic and molecular lesions. Breast cancer demonstrates these common principles, but the details are less clearly understood. What percent of cases is due to inherited risk (germline mutation) versus sporadic breast cancers (somatic mutation)? At the moment, we can estimate the inherited risk as 5% of breast cancers. But this estimate is likely to change as we discover more of the genes involved. What are the steps in evolution? Under the microscope we recognize the progression of hyperplasia, atypical hyperplasia, in situ carcinoma, and invasive cancer. The molecular evolution of breast cancer is less clearly understood. The linear sequence of molecular events that we saw in Figures 8.1 and 9.1 for colon and cervical cancer may not exist in as simple a form for breast cancer.


Breast Cancer Cervical Cancer Axillary Lymph Node Metastasis Breast Epithelium Sporadic Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 1996;274:2057–2059.PubMedCrossRefGoogle Scholar
  2. Kodish E, Wiesner GL, Mehlman M, et al. Genetic testing for cancer risk. How to reconcile the conflicts. JAMA. 1998;279:179–181.PubMedCrossRefGoogle Scholar
  3. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.CrossRefGoogle Scholar
  4. Olopade OI. Genetics in clinical cancer care—the future is now. N Engl J Med.1996; 335:1445–1456.CrossRefGoogle Scholar
  5. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. JAMA. 1997;278:1242–1250.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Dennis W. Ross
    • 1
  1. 1.Department of PathologyForsyth Medical CenterWinston-SalemUSA

Personalised recommendations